Lindbrook Capital, LLC Prelude Therapeutics Inc Call Options Transaction History
Lindbrook Capital, LLC
- $1.09 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRLD
# of Institutions
66Shares Held
36MCall Options Held
500Put Options Held
300-
Orbimed Advisors LLC San Diego, CA10.9MShares$10.4 Million0.38% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$9.62 Million0.14% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.02 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.03MShares$977,7390.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$959,8720.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $34.6M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...